Details of the Drug

General Information of Drug (ID: DMUY4VV)

Drug Name

PRA023

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 2	[1]
Ulcerative colitis	DD71	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial cell growth inhibitor (TNFSF15)	TTEST6I	TNF15_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05013905) A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04996797) A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
3	Clinical pipeline report, company report or official report of Prometheus Biosciences